Increased levels of NE-(carboxymethyl)lysine and NE-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: Correlation with markers of endothelial dysfunction

Nephrology Dialysis Transplantation

Volumn 19, Issue 3, 2004, Pages 631-636

  Lieuw A Fa, Mariska L M ^a   van Hinsbergh, Victor W M ^a,b   Teerlink, Tom ^a   Barto, Rob ^a   Twisk, Jos ^a   Stehouwer, Coen D A ^a   Schalkwijk, Casper G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Advanced glycation end products; Endothelial markers; Renal impairment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; N (CARBOXYETHYL)LYSINE; N (CARBOXYMETHYL)LYSINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; ENDOTHELIUM LESION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BLOOD COAGULATION FACTORS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LYSINE; MALE; MIDDLE AGED; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE-1;

EID: 1342306193     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg619     Document Type: Article

References (20)

1. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62: 1402-1407
2. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001; 38: S100-S106
3. Miyata T, Sugiyama S, Saito A, Kurokawa K. Reactive carbonyl compounds related uremic toxicity. Kidney Int Suppl 2001; 78: S25-S31
4. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9
5. Oya T, Hattori N, Mizuno Y et al. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem 1999; 274: 18492-18502
6. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842
7. Miyata T, van Ypersele dS, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of carbonyl stress in long-term uremic complications. Kidney Int 1999; 55: 389-399
8. Kislinger T, Fu C, Huber B et al. N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-31749
9. Abordo EA, Thornalley PJ. Synthesis and secretion of tumour necrosis factor-alpha by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. Immunol Lett 1997; 58: 139-147
10. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126
11. Schalkwijk CG, Poland DC, van Dijk W et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351-357
12. Isles CG, Paterson JR. Serum creatinine and urea: make the most of these simple tests. Br J Hosp Med 1996; 55: 513-516
13. Wagner Z, Wittmann I, Mazak I et al. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function. Am J Kidney Dis 2001; 38: 785-791
14. Degenhardt TP, Thorpe SR, Baynes JW. Chemical modification of proteins by methylglyoxal. Cell Mol Biol 1998; 44: 1139-1145
15. Peter K, Nawroth P, Conradt C et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17: 505-512
16. Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron 1998; 79: 399-407
17. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, NE-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271: 9982-9986
18. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates NE-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999; 104: 103-113
19. Sebekova K, Podracka L, Blazicek P, Syrova D, Heidland A, Schinzel R. Plasma levels of advanced glycation end products in children with renal disease. Pediatr Nephrol 2001; 16: 1105-1112
20. Califano F, Giovanniello T, Pantone P et al. Clinical importance of thrombomodulin serum levels. Eur Rev Med Pharmacol Sci 2000; 4: 59-66